INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Soleno Therapeutics, Inc. following a negative report on its product Vykat XR [1][2]. Group 1: Company Overview - Soleno Therapeutics, Inc. is publicly traded on NASDAQ under the ticker SLNO [1]. - The company's only product, Vykat XR, has been criticized for being overpriced and potentially unsafe for children [2]. Group 2: Legal Investigation - Pomerantz LLP is representing investors in the investigation concerning Soleno's officers and directors [1]. - The firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud [3]. Group 3: Market Reaction - Following the publication of Scorpion Capital's report on August 15, 2025, Soleno's stock price dropped by $5.73 per share, a decline of 7.41%, closing at $71.63 per share [2].